Chiron

Axovant Sciences appoints Dr. David Hung CEO, Marion McCourt as president and COO

Tuesday, April 18, 2017

Axovant Sciences, a clinical stage biopharmaceutical company focused on the treatment of dementia, announced that David Hung, M.D., has been named chief executive officer of Axovant Sciences, effective April 7, 2017. Dr. Hung, who also joined Axovant’s board of directors, succeeds founding chief executive officer Vivek Ramaswamy. Ramaswamy will continue to serve on Axovant’s board of directors and will lead parent company and majority owner Roivant Sciences as its full-time chief executive officer.

[Read More]

Painless Growth?

Monday, October 9, 2006

Big Pharma continues to expand into the vaccine market as Pfizer purchased privately owned PowderMed this week, hoping for an ouch-free entry into this segment. The vaccine market is suddenly looking golden to Big Pharma when just a few years ago it seemed that most drugmakers wouldn’t go near vaccines.

[Read More]